Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| G1 Therapeutics, Inc.GTHX · Entity 87413 | Chief Commercial Officer | February 06, 2020 | February 07, 2020 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Chief Commercial Officer | February 25, 2021 | March 01, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
G1 Therapeutics, Inc.
Report date February 06, 2020 · Filed February 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.08 · Expires 2030-02-06 | Direct | 30,000 |
Reported balance
After 2020-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-06 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares underlying this option vest as to 25% of the shares on February 06, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest as to 25% of the shares on February 06, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Karyopharm Therapeutics Inc.
Report date February 25, 2021 · Filed March 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,995 |
Reported balance
After 2021-02-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-02-25 · Grant · Acquired 15,849 · Balance 23,995 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 15,849 newly awarded RSUs and 8,146 shares of common stock, which include 646 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.56 · Expires 2031-02-24 | Direct | 43,177 |
Reported balance
After 2021-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-25 · Grant · Acquired 43,177 · Balance 43,177 F3: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022.
F2: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 15,849 newly awarded RSUs and 8,146 shares of common stock, which include 646 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020.
F3: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2021 Filed Mar 1, 2021 20:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 43,177 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015483 · doc4.xml · derivative · entry 2 DEMAREE JOHN · CIK 0001744959 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,177 Underlying: Common Stock · 43,177 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 15,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015483 · doc4.xml · nonDerivative · entry 1 DEMAREE JOHN · CIK 0001744959 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,995 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 15,849 newly awarded RSUs and 8,146 shares of common stock, which include 646 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020. Read SEC document |
| August 26, 2020 Filed Aug 27, 2020 16:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | PurchaseCommon Stock | 7,500 | $14.54 | $109,012.50 |
DisclosureSEC source: 0001209191-20-048515 · doc4.xml · nonDerivative · entry 1 DEMAREE JOHN · CIK 0001744959 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 17:30 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 151,200 | $0.00 Strike: $16.50 | $0.00 |
DisclosureSEC source: 0001209191-20-019703 · doc4.xml · derivative · entry 1 DEMAREE JOHN · CIK 0001744959 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,200 Underlying: Common Stock · 151,200 shares Expires 2030-03-15 F1 · derivative.exercise_date: This option was granted on March 16, 2020. The shares underlying this option vest as to 25% of the shares on March 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $21.08 | $0.00 |
DisclosureSEC source: 0001562180-20-001009 · primarydocument.xml · derivative · entry 1 DEMAREE JOHN · CIK 0001744959 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on February 06, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 2, 2019 17:28 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $19.56 | $0.00 |
DisclosureSEC source: 0001562180-19-000088 · primarydocument.xml · derivative · entry 1 DEMAREE JOHN · CIK 0001744959 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on January 02, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| December 10, 2018 Filed Dec 11, 2018 16:08 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | PurchaseCommon Stock | 1,000 | $33.15 | $33,151.10 |
DisclosureSEC source: 0001562180-18-004904 · primarydocument.xml · nonDerivative · entry 1 DEMAREE JOHN · CIK 0001744959 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Read SEC document |
| July 03, 2018 Filed Jul 6, 2018 16:47 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $45.50 | $0.00 |
DisclosureSEC source: 0001209191-18-041879 · doc4.xml · derivative · entry 1 DEMAREE JOHN · CIK 0001744959 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-07-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on July 3, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.